Low‐ and standard‐dose peginterferon alfa‐2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response
暂无分享,去创建一个
J. Hoofnagle | A. Neumann | M. Ghany | Y. Rotman | T. Heller | A. Modi | E. Doo | G. Lutchman | B. Borg | E. Rivera | T. Liang | J. Feld | A. Soza | R. Loomba